Available options in the management of non-typhi Salmonella

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 8, 2004, Pages 1737-1743

  Ruiz, Montserrat ^a   Rodríguez, Juan Carlos ^a   Escribano, Isabel ^a   Royo, Gloria ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Non typhi Salmonella; Salmonella infections; Salmonellosis

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; AZTREONAM; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; GATIFLOXACIN; GENTAMICIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; SULFONAMIDE; SULTAMICILLIN; TETRACYCLINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; CLINICAL TRIAL; DRUG MEGADOSE; GASTROENTERITIS; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; NONHUMAN; REVIEW; SALMONELLA; SALMONELLOSIS; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GASTROENTERITIS; HUMANS; IMMUNOCOMPROMISED HOST; SALMONELLA INFECTIONS;

EID: 4344675265     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.8.1737     Document Type: Review

References (55)

1. MEAD PS, SLUTSKER L, DIETZ V et al.: Food-related illness and death in the United States. Emerg. Infect. Dis. (1999) 5:607-625.
2. ALTEKRUSE SF, COHEN ML, SWERDLOW DL: Emerging foodborne diseases. Emerg. Infect. Dis. (1997) 3:285-293.
3. MANDELL GL, BENNET JE, DOLIN YR: Enfermedades Infecciosas. Principios y práctica (Volumen 2). Editorial Médica Panamericana, Madrid, Spain (2000):2846-2869.
4. RUIZ M, RODRIGUEZ JC, ELÍA M, ROYO G: Extra-intestinal infections caused by non-typhi Salmonella serotypes. 9 yrs'experience. Enferm. Infecc. Microbiol. Clin. (2000) 18(5):219-22.
5. SPERBER SJ, SCHLEUPNER CJ: Salmonellosis during infection with human immunodeficiency virus. Rev. Infect. Dis. (1987) 9(5)::926-934.
6. SIRINAVIN S, JAYANETRA P, LYANGKUL T: Predictors for extraintestinal infection in Salmonella enteritis in Thailand Pediatr. Infect. Dis. (1988) 7:44-48.
7. CRAVIOTO A, REYES RE, TRUJILLO F et al.: Risk of diarrhoea during the first year of life associated with initial and subsequent colonization by specific enteropathogens. Am. J. Epidemiol. (1990) 131:886-909.
8. BUCHWALD DS, BLASER MJ: A review of human salmonellosis: II. Duration of excretion following infection with non-typhi Salmonella. Rev. Infec. Dis. (1984) 6:345-356.
9. MILLER SI, HOHMANN EL PEGUES DA: Especies de Salmonella, incluida Salmonella typhi. En: Enfermedades Infecciosas. Principios y práctica (Volumen 2), Mandell GL, Bennet JE, Dolin YR (Eds), Editorial Médica Panamericana, Madrid, Spain (2000):2846-2869.
10. GOMEZ HF, CLEARY TG: Salmonella. In: Textbook of Pediatric Infectious Diseases (4th edn). Feigin RD, Cherry JD (Eds), WB Saunders Company, London, UK (1998):1321-1334.
11. THRELFALL EJ, FISHER IS, WARD LR, TSCHAPE H, GERNER-SMIDT P: Harmonization of antibiotic susceptibility testing for Salmonella: results of a study by 18 national reference laboratories within the European Union-funded Enter-net group. Microb. Drug. Resist. (1999) 5(3):195-200.
12. HELMS M, VASTRUP P, GERNER-SMIDT P, MOLBAK K: Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium. Emerg. Infect. Dis. (2002) 8(5):490-495.
13. THRELFALL EJ, FISHER IS, BERGHOLD C et al.: Antimicrobial drug resistance in isolates of Salmonella enterica from cases of salmonellosis in humans in Europe in 2000: results of international multi-centre surveillance. Euro. Surveill. (2003) 8(2):41-45.
14. THRELFALL EJ, WARD LR, SKINNER JA, GRAHAM A: Antimicrobial drug resistance in non-typhoidal salmonellas from humans in England and Wales in 1999: decrease in multiple resistance in Salmonella enterica serotypes Typhimurium, Virchow, and Hadar. Microb. Drug. Resist. (2000) 6(4):319-325.
15. LEEGAARD TM, CAUGNAT DA, FROHOLM LO, HOIBY EA, LASSEN J: Emerging antibiotic resistance in Salmonella typhimurium in Norway. Epidemiol. Infect. (2000) 125(3):473-480.
16. VAN DUIJKEREN E, WANNET WJ, HOUWERS DJ, VAN PELT W: Antimicrobial susceptibilities of salmonella strains isolated from humans, cattle, pigs, and chickens in the Netherlands from 1984 to 2001. J. Clin. Microbiol. (2003) 41(8):3574-3578.
17. STEPHEN JM, TOLEMAN MA, WALSH TR, JONES RN: Salmonella bloodstream infections: report from the SENTRY Antimicrobial Surveillance Program (1997-2001). Int. J. Antimicrob. Agents (2003) 22(4):395-405.
18. SIRVENT E, RUIZ M, RODRÍGUEZ JC, ROYO G: Serotipos y sensibilidad antibiótica del género Salmonella en Elche. Rev. Esp. Quimioter. (2002) 15:55-60.
19. RUIZ M, SIRVENT E, HERNANDEZ C, RODRIGUEZ JC, ROYO G: Evolution of resistance to quinolones in Salmonella enterica in our setting. Rev. Esp. Quimioter. (1999) 12(4):366-368.
20. HEURTIN-LE CORRE C, DONNIO PY, BONNIER M, TRAVERT MF, LACOURT A, AVRIL JL: Growing incidence of nalidixic acid resistance and sensitivity to quinolones in Salmonella typhimurium, strains isolated from man or animal. Pathol. Biol. (Paris) (1998) 46(8):587-590.
21. HEURTIN-LE CORRE C, DONNIO PY, PERRIN M, TRAVERT MF, AVRIL JL: Increasing incidence and comparison of nalidixic acid-resistant Salmonella enterica subsp. enterica serotype typhimurium, isolates from humans and animals. J. Clin. Microbiol (1999) 37(1):266-269.
22. THRELFALL EJ et al.: Increase in multiple antibiotic resistance in nontyphoidal salmonellas from human in England and Wales: a comparison of data for 1984 and 1996. Microb. Drug. Resist. (1997) 3:263-266.
23. GUPTA A, FONTANA J, CROWE C et al., The National Antimicrobial Resistance Monitoring System PulseNet Working Group: emergence of multidrug-resistant Salmonella enterica serotype Newport infections resistant to expanded-spectrum cephalosporins in the United States. J. Infect. Dis. (2003) 188(11):1707-1716.
24. DIGRANES A, SOLBERG CO, SJURSEN H et al.: Antibiotic susceptibilities of blood culture isolates of Enterobacteriaceae from six Norwegian hospitals 1991-1992. APMIS (1997) 105:854-860.
25. GORDILLO ME, SINGH K, MURRAY BE: In vitro activity of azithromycin against bacterial enteric pathogens. Antimicrob. Agents. Chemother. (1993) 37(5):1203-1205.
26. RAKITA RM, JACQUES-PALAZ K, MURRAY BE: Intracellular activity of azithromycin against bacterial enteric pathogens. Antimicrob. Agents. Chemother. (1994) 38:1915-1921.
27. POIREL L, GUIBERT M, BELLAIS S, NAAS T, NORDMANN P: Integron- and carbenicillinase-mediated reduced susceptibility to amoxicillin-clavulanic acid in isolates of multidrug-resistant Salmonella enterica serotype typhimurium DT104 from French patients. Antimicrob. Agents Chemother. (1999) 43(5):1098-1104.
28. CEBRIAN L, SIRVENT E, RODRIGUEZ DIAZ JC, RUIZ M, ROYO G: Characterisation of Salmonella spp. mutants produced by exposure to various fluoroquinolones. Int. J. Antimicrob. Agents. (2003) 22(2):134-139.
29. BAQUERO F, MARTINEZ-BELTRAN J, CANTON R: Criteria of the MENSURA group for the definition of the critical points of sensitivity to antibiotics. Enferm. Infecc. Microbiol. Clin. (1998) 16(2):85-92.
30. PARRY CM: Antimicrobial drug resistance in Salmonella enterica. Curr. Opin. Infect. Dis. (2003) 16(5):467-472.
31. CHIU CH, WU TL, SU LH et al.: The emergence in Taiwan of fluoroquinolone resistance in Salmonella enterica serotype choleraesuis. N. Engl. J. Med. (2002) 346(6):413-419.
32. PAVIA AT, SHIPMAN LD, WELLS JC et al.: Epidemiologic evidence that prior antimicrobial exposures decreases resistance to infection by antimicrobial-sensitive Salmonella. J. Infect. Dis. (1990) 161:255-260.
33. WORLD HEALTH ORGANIZATION: Control of Salmonella infections in animals and prevention of human foodborne Salmonella infections. Bull. World. Health. Organ. (1994) 72:831.
34. EDRINGTON TS, HARVEY RB, FARRINGTON LA, NISBET DJ: Evaluation of subtherapeutic use of the antibiotics apramycin and carbadox on the prevalence of antimicrobial-resistant Salmonella infection in swine. J. Food. Prot. (2001) 64(12):2067-2070.
35. PHILLIPS I, CASEWELL M, COX T et al.: Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. J. Antimicrob. Chemother. (2004) 53(1):28-52.
36. THRELFALL EJ, FROST JA, WARD LR, ROWE B et al.: Increasing spectrum of resistance in multiresistant Salmonella typhimurium. Lancet (1996) 347:1053-1054.
37. CHIU CH, LIN TY, OU JT: A clinical trial comparing oral azithromycin, cefixime and no antibiotics in the treatment of acute uncomplicated Salmonella enteritis in children. J. Paediatr. Child. Health. (1999) 35(4):372-374.
38. SIRINAVIN S, GARNER P: Antibiotics for treating salmonella gut infections. Cochrane Database Syst. Rev. (2000) (2):CD001167.
39. HOHMANN EL: Nontyphoidal salmonellosis. Clin. Infect. Dis. (2001) 32(2):263-269.
40. DONABEDIAN H: Long-term suppression of Salmonella aortitis with an oral antibiotic. Arch. Intern. Med. (1989) 149:1452-1453.
41. CHIAPPINI E, GALLI L, PECILE P, VIERUCCI A, DE MARTINO M: Results of a 5-year prospective surveillance study of antibiotic resistance among Salmonella enterica isolates and ceftriaxone therapy among children hospitalized for acute diarrhea. Clin. Ther. (2002) 24(10):1585-1594.
42. MOULIN F, SAUVE-MARTIN H, MARC E et al.: Ciprofloxacin after clinical failure of beta-lactam antibiotics in children with salmonellosis. Arch. Pediatr. (2003) 10(7):608-614.
43. NOLAN CM, WHITE PCJ: Treatment of typhoidal carrier with amoxicillin. JAMA (1978) 239:2352-2354.
44. SIRINAVIN S, THAVORNNUNTH J, SAKCHAINANONT B, BANGTRAKULNONTH A, CHONGTHAWONSATID S, JUNUMPORN S: Norfloxacin and azithromycin for treatment of nontyphoidal salmonella carriers. Clin. Infect. Dis. (2003) 37(5):685-691.
45. OSKOUI R, DAVIS W, GOMES M: Salmonella aortitis: a report of a successfully treated case with a comprehensive review of the literature. Arch. Intern. Med. (1993) 153:517-525.
46. JACOBSON MA, HAHN SM, GEBERDING JL et al.: Ciprofloxacin for salmonella bacteremia in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. (1989) 110:1027-1029.
47. CASADO JL, VALDEZATE S, CALDERON C et al.: Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients. J. Infect. Dis. (1999) 179(6):1553-1556.
48. PIDDOCK LJ, WHALE K, WISE R: Quinolone resistance in Salmonella: clinical experience. Lancet (1990) 335:1459.
49. BRAUMWALD E, FAUCI AS, KASPER DL, HAUSER SL, LONGO DL, JAMESON JL: Harrison's Principles of Internal Medicine (CD Rom) (15th edn). McGraw-Hill, New York, USA (2001).
50. CRUMP JA, BARRETT TJ, NELSON JT ANGULO FJ: Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin. Infect. Dis. (2003) 37(1):75-81.
51. AARESTRUP FM, WIUFF C, MOLBAK K, THRELFALL EJ: Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob. Agents. Chemother. (2003) 47(2):827-829.
52. WORKMAN MR, PHILPOTT-HOWARD J, BRAGMAN S, BRITO-BABAPULLE F, BELLINGHAM AJ: Emergence of ciprofloxacin resistance during treatment of Salmonella osteomyelitis in three patients with sickle cell disease. J. Infect. (1996) 32(1):27-32.
53. PERS C, SOGAARD P, PALLESEN L: Selection of multiple resistance in Salmonella enteritidis during treatment with ciprofloxacin. Scand. J. Infect. Dis. (1996) 28(5):529-531.
54. SIEPER J, FENDLER C, LAITKO S et al.: No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthritis. Rheum. (1999) 42(7):1386-1396.
55. MATTILA L, LEIRISALO-REPO M, PELKONEN P, KOSKIMIES S, GRANFORS K, SIITONEN A: Reactive arthritis following an outbreak of Salmonella Bovismorbificans infection.